Crystallization of LA and Adjuvant Mixtures in Cerebrospinal Fluid
Crystallization of Local Anesthetic and Adjuvant Mixtures in Cerebrospinal Fluid as a Model for Interstitial Space - a Semiquantitative in Vitro Trial
1 other identifier
observational
10
1 country
1
Brief Summary
Different mixtures of local anesthetics or local anesthetics with adjuvants that are known to precipitate in vitro are tested in human cerebrospinal fluid (CSF). CSF is gained from patients with normal pressure hydrocephalus scheduled for elective lumbar puncture. Patients signed an ICF for leftover samples. CSF will be assessed for pH values at different timepoints (t0-t3; 0 to 60 minutes). In a second step six commonly used mixtures of LA with LA or LAs with adjuvants will be mixed using the following mixture ratios: ropivacaine 0.75% + lidocaine 2% (ratio 1:1), ropivacaine 0,75% + mepivacaine 2% (ratio 1:1), ropivacaine 0.75% + chloroprocaine 2% (ratio 1:1), lidocaine 2% + sodium bicarbonate 8.4% (ratio 1:0.1), ropivacaine 0.75% + lidocaine 2% + sodium bicarbonate 8.4% (ratio 1:1:0.1) and ropivacaine 0.75% + dexamethasone (1.5:1). The used mixture ratios are inspired by commonly mixtures described in the current literature and have been proven to precipitate in vitro. For every mixture, a Grade of Crystallisation will be determined at baseline without CSF and then at t0 (immediately) to t3 (60 minutes) every 15 minutes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Sep 2025
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2025
CompletedFirst Submitted
Initial submission to the registry
September 18, 2025
CompletedFirst Posted
Study publicly available on registry
March 2, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 1, 2026
March 2, 2026
September 1, 2025
1 year
September 18, 2025
February 26, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Grade of Crystallisation
For the grading of detectable precipitations, a scale from 0 (no signs of precipitation / single particulates \< 10 μm) to 5 (heavy polymorphic crystallization: \> 100 solid bodies \> 10 μm, and \> 1 solid body \> 50 μm or \> 1 solid body \> 100 μm) will be used.
1 hour
Secondary Outcomes (2)
pH value and of CSF and CSF LA mixtures
1 hour
pCO2 of CSF and CSF LA mixtures
1 hour
Study Arms (1)
Patients with normal pressure hydrocephalus scheduled for elective lumbar puncture
Patients with normal pressure hydrocephalus scheduled for elective lumbar puncture
Eligibility Criteria
patients with normal pressure hydrocephalus scheduled for elective lumbar puncture.
You may qualify if:
- Patients with normal pressure hydrocephalus scheduled for elective lumbar puncture.
You may not qualify if:
- Age \< 18 years
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Medical University Innsbruck
Innsbruck, Tyrol, 6020, Austria
Related Publications (1)
Hoerner E, Stundner O, Putz G, Steinfeldt T, Mathis S, Gasteiger L. Crystallization of ropivacaine and bupivacaine when mixed with different adjuvants: a semiquantitative light microscopy analysis. Reg Anesth Pain Med. 2022 Jun 23:rapm-2022-103610. doi: 10.1136/rapm-2022-103610. Online ahead of print.
PMID: 35738668BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Elisabeth Gasteiger, MD PhD
Medical Unicersity Innsbruck
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 18, 2025
First Posted
March 2, 2026
Study Start
September 1, 2025
Primary Completion (Estimated)
September 1, 2026
Study Completion (Estimated)
September 1, 2026
Last Updated
March 2, 2026
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- ANALYTIC CODE
- Time Frame
- Data will only be shared on a reasonable request.
- Access Criteria
- Data will only be shared on a reasonable request.
Data will only be shared on a reasonable request.